Last edited by Moran
Sunday, August 2, 2020 | History

1 edition of Therapy-related second malignancies found in the catalog.

Therapy-related second malignancies

Therapy-related second malignancies

  • 252 Want to read
  • 6 Currently reading

Published by Saunders in Philadelphia, London .
Written in English


Edition Notes

StatementJoseph H. Antin and Lawrence N. Shulman, guest editors.
SeriesHematology/oncology clinics of North America -- 7/2
ContributionsAntin, Joseph H., Shulman, Lawrence N.
ID Numbers
Open LibraryOL21639419M

  Human Malignancies: New Approaches to Diagnosis and Therapy: Medicine & Health Science Books @   Netherlands Cancer Institute; PMID "Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer." (van den Belt-Dusebout AW, J Clin Oncol. Oct 1;25(28)).

MEDLINE Abstracts: Second Malignancies. MEDLINE Abstracts: Second Malignancies. What's new about therapy-related malignancies in cancer . Hodgkin's lymphoma (HL) is one of the most curable hematologic diseases with an overall response rate over 80%. However, despite this therapeutic efficacy, HL survivors show a higher morbidity and mortality than other people of the same age because of long-term therapy-related events. In the last decades, many efforts have been made to reduce these effects through the reduction of chemotherapy.

  The median latency to second malignancy was years (range: –). Two hundred twenty‐eight (44%) patients developed a second malignancy in the first 5 years after their cHL diagnosis, (27%) between years 5–10, and (30%) of the second malignancies were diagnosed greater than 10 years after their index diagnosis.   Researchers used the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute to obtain diagnostic and demographic data patients with CML diagnosed between and Of these patients, (%) exhibited second malignancies, with 2 or more malignancies present in 34 patients.


Share this book
You might also like
Labour laws and regulations of the Peoples Republic of China.

Labour laws and regulations of the Peoples Republic of China.

Bisk Cpa Ready Auditing And Attestation Audio Tutor 2005-2006: Comprehensive Cpa Exam Review :version 5.0 (Cpa Ready)

Bisk Cpa Ready Auditing And Attestation Audio Tutor 2005-2006: Comprehensive Cpa Exam Review :version 5.0 (Cpa Ready)

Power House QTP.

Power House QTP.

Clough, 1702. The New-England almanack for the year of our Lord, MDCCII. ...

Clough, 1702. The New-England almanack for the year of our Lord, MDCCII. ...

Market research and industry surveys

Market research and industry surveys

Exploring the Palos Verdes Peninsula

Exploring the Palos Verdes Peninsula

Public communication

Public communication

Proceedings of the 1987 Electronic Design AutomationConference

Proceedings of the 1987 Electronic Design AutomationConference

Alternate circulator design concept no. 1 fo a 300 MW(e) GCFR demonstration plant

Alternate circulator design concept no. 1 fo a 300 MW(e) GCFR demonstration plant

The chemistry of glycerides

The chemistry of glycerides

The summit

The summit

Investing in KLSE stocks and futures

Investing in KLSE stocks and futures

The Lady Elizabeth

The Lady Elizabeth

Ergodic theory in statistical mechanics

Ergodic theory in statistical mechanics

Papers presented at the Fifth European Conference on Mixing

Papers presented at the Fifth European Conference on Mixing

Machines who think

Machines who think

Therapy-related second malignancies Download PDF EPUB FB2

Radiation has long been associated with the development of primary cancers and, when used as treatment, imparts a risk for the development of a second cancer.

Typically, second tumors occur within or at the margin of the radiated field. Bone and soft-tissue sarcomas are the most frequent SMNs following radiation therapy, but skin, brain, thyroid, and breast cancers also can occur Radiation Cited by: 4.

The specific risk of dying from a second cancer was increased 6 times compared to the normal population. In patients treated Therapy-related second malignancies book they were younger than 21 years of age, the risk was even greater with a fold increase in death from a second cancer.

The risk of second cancers was the greatest in those patients who required the most treatment. COVID Resources. Reliable information about the coronavirus (COVID) is available from the World Health Organization (current situation, international travel).Numerous and frequently-updated resource results are available from this ’s WebJunction has pulled together information and resources to assist library staff as they consider how to handle coronavirus.

The therapeutic success has been accompanied by concerns for long-term side-effects of treatments, including therapy-related second malignancies (Boyer and Raghavan ).

Due to their low curability, most second cancers significantly compromise the prognosis of these patients, often nulliflying the success of curing the primary : S. Formenti, F. Corso. It's not possible to predict who might get a second cancer, but sometimes having cancer treatment can put a person at higher risk for second cancers.

As more new treatments emerge and standard treatments continue to be used, studies continue to look at how genetics and different cancer treatments interact, as well as links between the. Treatment-related factors are presumed to be responsible for the elevated risk of myelodysplastic syndrome, lung cancer, non-Hodgkin's lymphoma and acute myeloid leukemia in patients treated with.

Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype ASH Education Book, (), pp. et y-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients.

Cancer Biol Ther, 14 (), pp. Development of a second malignancy is one of the most serious late effects in survivors of both childhood and adult-onset cancers.

Patterns of second malignancy risk across the age spectrum can differ in terms of the types of second malignancies observed, magnitude of the risks, the latency period, associated risk factors, and modifying influences.

With improving survivorship in chronic lymphocytic leukemia (CLL), the risk of second primary malignancies (SPMs) has not been systematically addressed. Differences in risk.

SECOND CANCER FOLLOWING CHEMOTHERAPY Furthermore, although possible confounders, such as age, sex, and ethnic origin, have been taken into account by most studies using an external comparison population, the method of indirect standardization which has been used does not insure comparability across different studies.

Journals & Books; Register Sign in. Sign in CiteScore. Impact Factor. Articles & Issues. About. Publish. Latest issue All issues. Search in this journal. Therapy-Related Second Malignancies. Edited by Joseph H. Antin, Lawrence N.

Shulman. Volume 7, Issue 2, select article Treatment of Therapy-Related Acute Myelogenous Leukemia. The Cancer-Fighting Kitchen, Second Edition: Nourishing, Big-Flavor Recipes for Cancer Treatment and Recovery [A Cookbook] and Love for Women with Breast Cancer (Inspirational Books for Women, Breast Cancer Books, Motivational Books for Women, Encouragement Gifts Gina L Mulligan.

out of 5 stars Hardcover. $ # The Emperor of. Abstract. Second malignancies are a major cause of morbidity and mortality among Hodgkin lymphoma (HL) survivors. Several epidemiologic studies have demonstrated increased risks of second solid cancers and acute leukemia associated with extended-field radiation therapy (RT) and alkylating chemotherapy agents, respectively.

Compared to survivors of most other childhood cancers, patients with Ewing sarcoma appeared to be at higher risk of SMN. In one study, of 4, 5‐year survivors of all types of childhood cancer developed second malignancies 25 years after.

With prostate cancer, the most common areas for second cancers are in the lower body, but a study of patients who had squamous cell carcinoma of the head and neck that found the most common.

ic malignancies include a very large number of genetically diverse diseases (Lichtman, ). To provide specialized care for patients with he-matologic malignancies, nurses must keep pace with advances in medicine and science.

The pur - pose of this book is to provide a detailed review of these complex malignancies. The context for the review. malignancy: [ mah-lig´nan-se ] a tendency to progress in virulence. In popular usage, any condition that, if uncorrected, tends to worsen so as to cause serious illness or death.

Cancer. Similarly, he says skin cancer is also very prevalent among second-diagnosis situations. Family History. He also says it is advisable to learn about family histories, and get to know this for both sides of the family.

"Knowing about genetics is a good base for treatment. Ask questions, talk to relatives, and keep records," he advises. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease.

N Engl J Med. ; Abstract; Bhatia S, Krailo M, Schwartz C, et al. Therapy-related myelodysplasia following treatment of children with osteosarcoma. Chemotherapy-related tumors tend to plateau after 5 years from diagnosis of the primary malignancy, in contrast to radiation therapy–related tumors, which have an increased prevalence over time (, 4, 17).

Because of this short latency period, secondary AML is the most likely SMN to occur during the first 5 years after treatment, although it. The book focuses on the management of disease-related manifestations and treatment-related side effects and toxicities.

You’ll find details on forms of hematologic malignancies, including leukemia and lymphoma, Hodgkin lymphoma, mature T-cell and NK-cell neoplasms, and multiple myeloma. Micro-AbstractFollicular lymphoma (FL) is a common low-grade lymphoma with excellent long-term survival in the present era.

We used the Surveillance, Epidemiology, and End Results registry to identify patients with FL from to and study the incidence and risk factors for the development of second primary malignancies (SPMs). During a median follow-up period of 71 .Therapy-Related Solid Tumors Radiation induces solid tumors, usually within the radiation field.

[4,10,11,15,43] In contrast to t-MDS/AML, the latency for therapy-related solid tumors is usually longer than 10 years. The risk is highest when radiation exposure occurs at a younger age, [4,9,11,] and rises with increasing doses of radiation and with increasing follow-up from radiation.